Regeneron Pharmaceuticals | REGN - PE Price to Earnings


Regeneron Pharmaceuticals reported 25.14 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amgen 19.84 5.47 Mar/2026
Astellas Pharma 15.48 8.16 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
Incyte 15.35 0.51 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
J&J 29.43 4.9 Jun/2026
Kyowa Hakko Kirin 15.88 3.85 Mar/2026
Merck 16.52 2.6 Mar/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 28.09 807.38 Mar/2026
Novartis 20.17 2.32 Mar/2026
Novartis 21.36 3.57 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 20.87 5.12 Mar/2026
Sarepta Therapeutics 27.27 0 Dec/2025
Teva Pharmaceutical Industries 10.07 0.04 Mar/2026
United Therapeutics 20.42 3.1 Mar/2026
Vertex Pharmaceuticals 25.82 0.33 Mar/2026